168
Participants
Start Date
April 30, 2009
Primary Completion Date
July 31, 2014
Study Completion Date
October 31, 2014
Ixabepilone
40 mg/m2 IV infusion over 3 hours on day 1 of a 21 day cycle for 6 cycles
Cyclophosphamide
600 mg/m2 IV infusion per institutional guidelines on day 1 of a 21 day cycle for 6 cycles
Center for Cancer and Blood Disorders, Bethesda
National Capital Clinical Research Consortium, Bethesda
Virginia Cancer Institute, Richmond
South Carolina Oncology Associates, PA, Columbia
Northeast Georgia Medical Center, Gainesville
Medical Oncology Associates of Augusta, Augusta
Aventura Medical Center, Aventura
Watson Clinic Center for Cancer Care and Research, Lakeland
Florida Cancer Specialists, Fort Myers
Tennessee Oncology, Nashville
Chattanooga Oncology Hematology Associates, Chattanooga
Family Cancer Center, Collierville
Oncology Hematology Care, Cincinnati
Providence Medical Group, Terre Haute
St. Louis Cancer Care, Chesterfield
Methodist Cancer Center, Omaha
Cancer Centers of Southwest Oklahoma, Lawton
South Texas Oncology and Hematology, San Antonio
Mercy Hospital, Portland
Hematology Oncology Associates of Northern NJ, Morristown
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
SCRI Development Innovations, LLC
OTHER